The use of GM-CSF as an adjunct to autologous/syngeneic bone marrow transplantation: a prospective randomized controlled trial
- PMID: 1878732
The use of GM-CSF as an adjunct to autologous/syngeneic bone marrow transplantation: a prospective randomized controlled trial
Similar articles
-
RHU GM-CSF shortens aplasia duration after ABMT in non-Hodgkin's lymphoma: a randomized placebo-controlled double-blind study.Bone Marrow Transplant. 1991;7 Suppl 2:82. Bone Marrow Transplant. 1991. PMID: 1878733 Clinical Trial. No abstract available.
-
Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) reduces infection-related mortality after allogeneic T-cell depleted BMT.Bone Marrow Transplant. 1991;7 Suppl 2:83. Bone Marrow Transplant. 1991. PMID: 1908729 Clinical Trial. No abstract available.
-
The use of granulocyte-macrophage colony-stimulating factor in bone marrow transplantation.Semin Hematol. 1992 Oct;29(4 Suppl 3):14-8. Semin Hematol. 1992. PMID: 1362821 Review.
-
Human recombinant GM-CSF in allogeneic bone marrow transplantation for leukaemia: double-blind placebo controlled trial.Bone Marrow Transplant. 1991;7 Suppl 2:85-6. Bone Marrow Transplant. 1991. PMID: 1878735 Clinical Trial.
-
The use of recombinant human granulocyte macrophage colony-stimulating factor in autologous bone marrow transplantation.Bone Marrow Transplant. 1991;7 Suppl 3:24-7. Bone Marrow Transplant. 1991. PMID: 1855082 Review.
Cited by
-
Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: an economic analysis of a randomised, double-blind, placebo-controlled trial.Pharmacoeconomics. 1994 Jul;6(1):42-8. doi: 10.2165/00019053-199406010-00005. Pharmacoeconomics. 1994. PMID: 10172083 Clinical Trial.
-
The side-effect profile of GM-CSF.Infection. 1992;20 Suppl 2:S124-7. doi: 10.1007/BF01705031. Infection. 1992. PMID: 1493936 Review.
-
Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.Drugs. 1992 Apr;43(4):516-560. doi: 10.2165/00003495-199243040-00008. Drugs. 1992. PMID: 28421558
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical